Suzhou, China · Founded 2020 · Privately Held (backing)
Developer of TCR-T (T-cell receptor-based therapy), an immune cell therapy designed for solid tumors. Neowise Biotechnology is based in Suzhou, China and was founded in 2020. Its last reported valuation was $229 million in Oct 2025. It has raised $57.1 million.
Last reported valuation
$229.1M
Oct 2026
Priced at
—
Total raised
$57.1M
Last round
—
Cap table — not yet on record
Neowise Biotechnology's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Neowise Biotechnology with a free account
·The complete investor list: 15 names
·Watch Neowise Biotechnology: the Monday email on marks, rounds and moves
